Resverlogix Gets Health Canada Approval for Apabetalone Trial

Pharmaceutical Investing

Resverlogix received approval from Health Canada to move forward with a clinical trial on their lead compound RVX 208 or apabetalone, for patients with Fabry disease.

Resverlogix (TSX:RVX) received approval from Health Canada to move forward with a clinical trial on their lead compound RVX 208 or apabetalone, for patients with Fabry disease.
As quoted in the press release:

Donald McCaffrey, President and CEO, stated, “We are extremely pleased to receive approval for this clinical trial in Canada. Canada possesses some of the world’s preeminent experts in the orphan Fabry disease field and a well-established patient registry. Working with us throughout the trial are Dr. Michael West, Principal Investigator, Canadian Fabry Disease Initiative, Professor, Department of Medicine, Dalhousie University, Halifax NS and Dr. Aneal Khan, Associate Professor, Departments of Medical Genetics, Paediatrics, Alberta Children’s Hospital, Calgary, AB. Apabetalone is known to regulate key biomarkers associated with this rare disease and may potentially offer an alternative for patients with this rare disorder.”

Click here to read the full press release.

Source: www.newswire.ca

alberta canada disease genetics health health canada patient patients rare disease us Pharmaceutical Investing